Description

Inotuzumab Ozogamicin is a targeted antibody-drug conjugate (ADC) designed for precision oncology applications. This innovative therapeutic agent combines a monoclonal antibody with a potent cytotoxic payload to selectively deliver its effect. It is primarily utilized in the research, development, and manufacturing of advanced cancer treatments, particularly for specific hematologic malignancies. Our supply ensures high purity and consistency, critical for pharmaceutical development and clinical use.

Application

• Pharmaceutical Active Ingredient (API): Core component in the formulation of targeted cancer therapeutics.
• Oncology Research & Development: Used in preclinical and clinical studies to investigate mechanisms of action and therapeutic efficacy.
• Bioconjugation & ADC Manufacturing: Serves as a reference standard or key intermediate in the synthesis of antibody-drug conjugates.
• Cell Biology Studies: Employed in vitro to study targeted cell killing and internalization pathways in specific cancer cell lines.
• Quality Control & Analytical Testing: Used as a certified reference material for HPLC, LC-MS, and other analytical methods.
• Process Development & Scale-up: Supports optimization of manufacturing processes for biologics in GMP environments.

Basic Information

Product Name	Inotuzumab Ozogamicin
CAS No.	635715-01-4
Molecular Formula	C₁₀₂H₁₃₀N₁₈O₃₃S₂ (Representative for the conjugate)
Molecular Weight	~160 kDa (Antibody conjugate)
Synonyms	CMC-544; InO; WAY-207294; Anti-CD22 monoclonal antibody-calicheamicin conjugate; Besponsa (Brand Name); Anti-CD22 ADC; Inotuzumab ozogamicin; CD22-directed antibody-drug conjugate
EINECS	Contact for details

Quality Control

Our Inotuzumab Ozogamicin is produced and handled under strict quality systems to meet the exacting standards of pharmaceutical research and development. Each batch is supported by comprehensive analytical data to ensure identity, purity, and biological activity. Certificates of Analysis (COA) detailing specifications such as purity (by HPLC), protein concentration, endotoxin levels, and sterility (where applicable) are provided. We adhere to relevant GMP and ICH guidelines for advanced pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below for long-term stability. This product is hygroscopic (moisture-sensitive) and should be handled under controlled, dry conditions to prevent degradation. For short-term use, aliquots may be stored at 2-8°C. Avoid repeated freeze-thaw cycles.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or solid
Identification (HPLC/MS)	Conforms to reference standard
Purity (HPLC)	≥ 95.0%
Protein Content (UV/A280)	As per COA
Drug-to-Antibody Ratio (DAR)	~ 5 - 7 (Typical)
Endotoxin	< 10 EU/mg
Moisture Content (KF)	< 5.0%
Biological Activity (Binding)	Confirmed by ELISA or SPR

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.